

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Tradsmark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/769,508	01/26/2001	Susan G. Stuart	BEBIO-111 CI	8243	
75	90 06/25/2002				
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.			EXAMINER		
Arlington Court Suite 1400	thouse Plaza I	KAUFMAN, CLAIRE M			
2200 Clarendor	n Boulevard				
Arlington, VA	22201		ART UNIT	PAPER NUMBER	
			1646	0	
			DATE MAILED: 06/25/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspio.gov

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
			EXAMINER	
			ART UNIT	PAPER
				8
			DATE MAILED	:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

The communication filed 1/28/02 is not fully responsive to the Office communication mailed 11/27/01 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132. While a CRF and Sequence Listing was provided, there appears to be no sequence corresponding to the nucleotide sequence shown in Figure 16E. When a sequence is presented in a drawing, regardless of the format or the manner of presentation of that sequence in the drawing, the sequence must still be included in the Sequence Listing and a sequence identifier ("SEQ ID NO:X") must be used either in the drawing or in the Brief Description of the Drawings. See MPEP 2422.02.

Since the reply appears to be <u>bona fide</u> attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of **ONE** (1) **MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Claire Kaufman, Art Unit 1646, whose telephone number is (703) 305-5791.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

Claire M. Kaufman

Patent Examiner, AU 1646

	Application No.	Applicant(s)			
	09/769,508	STUART ET AL.			
Notice to Comply	Examiner	Art Unit			
	Claire M. Kaufman	1646			
NOTICE TO COMPLY WITH REQUIREMENT NUCLEOTIDE SEQUENCE AND/OR AMINO			INING		
Applicant must file the items indicated below within the t avoid abandonment under 35 U.S.C. § 133 (extensions	ime period set the Office action to of time may be obtained under the	which the Notice e provisions of 37	e is attached to CFR 1.136(a)).		
The nucleotide and/or amino acid sequence disclosure of for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.8	contained in this application does 825 for the following reason(s):	not comply with t	he requirements		
1. This application clearly fails to comply with the red directed to the final rulemaking notice published at 5 the effective filing date is on or after July 1, 1998, se 1998) and 1211 OG 82 (June 23, 1998).	i5 FR 18230 (May 1, 1990), and 1	114 OG 29 (May	15, 1990). If		
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).					
3. A copy of the "Sequence Listing" in computer read 37 C.F.R. 1.821(e).	dable form has not been submitte	d as required by			
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."					
5. The computer readable form that has been filed vunreadable as indicated on the attached CRF Diske submitted as required by 37 C.F.R. 1.825(d).	with this application has been four tte Problem Report. A Substitute	nd to be damaged computer readab	d and/or ole form must be		
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).					
□ 7. Other: see attached					
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF	F) copy of the "Sequence Listing".				
igtimes An initial or <u>substitute</u> paper copy of the "Sequence specification.	Listing", as well as an amendmer	nt directing its ent	ry into the		
A statement that the content of the paper and comp	puter readable copies are the san	ne and, where ap	plicable, include		

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY